Muniyappa R, et al. - A personalized statin benefit approach based on absolute risk reduction over 10 years (ARR₁₀ benefit threshold ≥2.3%) has been proposed as a novel approach to aid clinical decision-making for the primary prevention of atherosclerotic cardiovascular disease. Among prospectively recruited asymptomatic subjects with low/intermediate Framingham risk score (< 20%), researchers compared the predicted ARR₁₀ obtained in each individual with plaque burden detected by coronary computed tomography angiography. They noted statin therapy to be most likely of greater benefit to individuals with higher coronary plaque burden even among asymptomatic individuals with low cardiovascular risk.